HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 01.wnl.0000204294.28189.03v1 66/6/919    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schifitto, G. Articles by Gelbard, H. Search for Related Content PubMed PubMed Citation Articles by Schifitto, G. Articles by Gelbard, H. Related Collections HIV All Clinical trials Clinical trials Observational study (Cohort, Case control) HIV dementia Antiepileptic drugs

Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

From the Departments of Neurology (G.S., K.C., M.G., H.G.), Biostatistics (D.R.P.), and Radiology (J.Z., H.N.), University of Rochester Medical Center, Rochester, NY; and Departments of Pharmacology and Experimental Neuroscience (H.E.G.) and Radiology (M.B.), University of Nebraska Medical Center, Omaha.

Address correspondence and reprint requests to Dr. Giovanni Schifitto, Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620; e-mail: giovanni.schifitto{at}ctcc.rochester.edu

In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the March 28 issue to find the title link for this article.

This article was previously published in electronic format as an Expedited E-Pub at www.neurology.org.

Supported by NIH grants P01 MH64570, U01 AI27658, and R01 MH64409 and General Clinical Research Center grant M01 RR00044 from the National Center for Research Resources, NIH.

Disclosure: The authors report no conflicts of interest.

Received August 10, 2005. Accepted in final form December 29, 2005.

This article has been cited by other articles:

				R. DiCenzo, D. R. Peterson, K. Cruttenden, P. Mariuz, N. L. Rezk, J. Hochreiter, H. Gelbard, and G. Schifitto Effects of Minocycline and Valproic Acid Coadministration on Atazanavir Plasma Concentrations in Human Immunodeficiency Virus-Infected Adults Receiving Atazanavir-Ritonavir Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3035 - 3039. [Abstract] [Full Text] [PDF]

				G. Schifitto, J. Zhang, S. R. Evans, N. Sacktor, D. Simpson, L. L. Millar, V. L. Hung, E. N. Miller, E. Smith, R. J. Ellis, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment Neurology, September 25, 2007; 69(13): 1314 - 1321. [Abstract] [Full Text] [PDF]